Join the Oncology Voice Network. Join for Free
Role of the MSL in launch preparedness for new products and indications
MSL roles drug launch preparation medical affairs strategy pharmaceutical trends field medical leadership

Role of the MSL in launch preparedness for new products and indications


Share This Article


Summary

Matt Goodwin joins Tom Caravela to discuss the crucial role of MSLs in drug launch preparation and leadership. Matt shares his career journey and insights from his experiences at MAPS. They delve into the training, expectations, and success factors for MSLs during launches, addressing common stressors and establishing key milestones. The conversation highlights common pitfalls and offers advice for MSLs navigating launch phases. They examine the skills and motivation needed for evaluating MSL candidates and discuss future trends in pharma and MSL roles. The episode concludes with a call for listener feedback and subscription.

Matt Goodwin, Vice President Medical Affairs at SC Pharmaceuticals discusses the role of the MSL in preparation and strategy for launch preparedness of new products/indications.

Learn more about…

👉 The importance of preparation and timeline for launch
👉 Training and resources for launch mode
👉 The role of field medical leadership
👉 Milestones and success factors to consider
👉 The stressors to be aware of and anticipate during a launch

Click for Source
MSL roles, drug launch preparation, medical affairs strategy, pharmaceutical trends, field medical leadership

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
No “D”…No Problem: Finding Success WITHOUT a Doctorate
Partner Avatar MSL Talk: Tom Caravela, Greg Auclair

No “D”…No Problem: Finding Success WITHOUT a Doctorate

Podcast
Motivation Means NOTHING…
Partner Avatar MSL Talk: Tom Caravela

Motivation Means NOTHING…

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN